Table 2 Clinical manifestations and prognosis of previously reported CAEBV patients with coronary artery lesions
From: Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis
Pt | Sex | Onset age (years) | IM-like symptoms | Coronary artery lesions | Other cardiovascular complications | Other organ manifestations | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Occurrence age (years) | Affected branch | Coronary diameter | Large-vessel arteritis | Myocarditis | Others | |||||
1 | M | 4 | L, H | 4 | NA | NA | No | No | No | Interstitial pneumonitis, Sjögren syndrome |
2 | F | 5 | L, H | 5 | NA | NA | Abdominal aortic aneurysm | No | No | Interstitial pneumonitis |
3 | M | 2 | F, L, H | 2 | NA | NA | Dilation of the sinus of Valsalva | No | No | Interstitial pneumonitis |
4 | F | 6 | F, L, H | 6 | NA | NA | No | No | Pericarditis | Interstitial nephritis |
5 | F | 5 | F, H | 5 | NA | NA | Dilation of the sinus of Valsalva | No | Pericarditis | No |
6 | F | 2 | F, H | 4 | LCA | 4 mm | No | No | No | Gastrointestinal tract, hypersensitivity to mosquito bites, hydroa vacciniforme |
7 | M | 5 | F, H | 8 | LCA | 5 mm | No | No | No | No |
8 | M | 6 | F, H | 10 | LCA | 4.5 mm | No | No | No | No |
9 | F | 9 | F, H | 18 | LCA, RCA | 4 mm in RCA, 4 mm in LCA | No | No | No | No |
10 | M | 11 | H | 14 | LCA, RCA | NA | No | No | PAH, junctional ectopic tachycardia | No |
11 | F | 10 | F, H | 10 | LCA, RCA | NA | Dilation of bilateral common carotid and subclavian arteries, abdominal aorta and major branches, and bilateral common iliac arteries | No | No | No |
12 | M | 2 | F, H, L | 2 | LCA, RCA | 6 mm in RCA, 3 mm in LCA | No | No | No | No |
13 | F | 7 | F, H, L | 7 | NA | NA | No | No | Pericardial effusion | No |
14 | M | 2 | F, H, L | 2 | LAD, LCX | 6 mm in LMCA | No | No | No | No |
15 | F | 5 | F, H | 5 | LCA, RCA | 8 mm in RCA, 5 mm in LCA | 38 mm in the sinus of Valsalva, thoracic and abdominal aortic aneurysms | No | No | No |
16 | M | 6 | F, H | 8 | NA | NA | No | No | No | No |
17 | F | NA | NA | NA | LCA, RCA | NA | No | No | No | No |
18 | F | 16 | F, H, L | 16 | RCA (multiple stenoses and dilation) | NA | Aneurysms involving the aorta and its major branches, and bilateral common iliac arteries | No | No | No |
19 | F | 6 | F, H, L | 6 | LMCA, RCA | 5 mm in LMCA, 8.2 mm in RCA | No | No | No | No |
20 | M | 5 | NA | 9 | LAD, RCA | NA | Dilatation of aortic sinus, minor dilatation of abdominal aortic stem and the distal section of superior mesenteric artery | No | PAH, cardiac insufficiency | Skin ulcers |
Pt | Sex | Onset age (years) | IM-like symptoms | EBV status | Therapies—HSCT | Prognosis | Reports | ||
|---|---|---|---|---|---|---|---|---|---|
Cell type | EBV copies (in PB)/EBERs | Abnormal EBV antibodies | |||||||
1 | M | 4 | L, H | T | EBERs (+) | Yes | No | Died (streptococcus pneumoniae) within 36 months from onset | Nakagawa et al. [25] |
2 | F | 5 | L, H | T | EBERs (+) | Yes | No | Died (respiratory failure) within 13 months from onset | Nakagawa et al. [25] |
3 | M | 2 | F, L, H | NA | EBV-DNA in cardiac tissues | Yes | No | Died within 5 years from onset | Kikuta et al. [26] |
4 | F | 6 | F, L, H | NA | EBV-DNA in cardiac and aortic tissues | Yes | No | Died within 5 years from onset | Kikuta et al. [26] |
5 | F | 5 | F, H | NA | EBV-DNA in cardiac tissues | Yes | No | Died within 5 years from onset | Kikuta et al. [26] |
6 | F | 2 | F, H | NK | 3 × 103 copies/mL | No | Yes | Alive and disease free | Muneuchi et al. [12] |
7 | M | 5 | F, H | T | 3 × 103 copies/mL | Yes | Yes | Died at 14 years | Muneuchi et al. [12] |
8 | M | 6 | F, H | T | 5 × 104 copies/mL | Yes | Yes | Alive and disease free | Muneuchi et al. [12] |
9 | F | 9 | F, H | γδT | 9 × 102 copies/mL | Yes | No | Died at 18 years | Muneuchi et al. [12] |
10 | M | 11 | H | NA | 8.2 × 104 copies/μg DNA | Yes | Yes | Died (septic shock and multiple organ failure) within 13 days after transplantation | Fukuda et al. [27] |
11 | F | 10 | F, H | T | EBERs (+) | Yes | No | Died (respiratory failure due to diffuse alveolar damage) | Murakami et al. [28] |
12 | M | 2 | F, H, L | T | EBV-DNA in PBMC | Yes | NA | NA | Kikuta et al. [29] |
13 | F | 7 | F, H, L | T | EBV-DNA in pericardial effusion | Yes | Yes | Died (failure of umbilical cord blood transplantation) | Toubo et al. [30] |
14 | M | 2 | F, H, L | T | NA | Yes | No | NA | Kobayashi et al. [31] |
15 | F | 5 | F, H | T | EBERs (+) | Yes | No | Died (acute respiratory failure) within 13 months from onset | Nakagawa et al. [14] |
16 | M | 6 | F, H | T | NA | Yes | NA | NA | Ohga et al. [32] |
17 | F | NA | NA | NA | NA | NA | Yes | NA | Nishimura et al. [33] |
18 | F | 16 | F, H, L | NA | 2.8 × 104 copies/mL | NA | No | NA | Jiang et al. [34] |
19 | F | 6 | F, H, L | NA | 3.72 × 107 copies/mL | NA | No | NA | Xie et al. [35] |
20 | M | 5 | NA | NA | 4.53 × 103 copies/mL in plasma, EBERs (+) | Yes | No | NA | Ba et al. [36] |